63 related articles for article (PubMed ID: 36586091)
1. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding.
Goto C; Okimoto K; Matsusaka K; Matsumura T; Akizue N; Ohta Y; Taida T; Saito K; Kato J; Kato N
Clin J Gastroenterol; 2023 Apr; 16(2):159-163. PubMed ID: 36586091
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitor Associated Multiple Gastric Hyperplastic Polyps With Uncontrollable Bleeding: A Case Report.
Nakashima M; Naoe H; Komohara Y; Waki K; Miyamoto H; Sakai Y; Kojima T; Kanemitsu T; Yao K; Tanaka Y
In Vivo; 2024; 38(3):1465-1469. PubMed ID: 38688629
[TBL] [Abstract][Full Text] [Related]
3. Long-term endoscopic change of gastric polyp associated with administration of vonoprazan.
Ochiai Y; Ito S; Kikuchi D; Hoteya S
Clin J Gastroenterol; 2024 Apr; ():. PubMed ID: 38575803
[TBL] [Abstract][Full Text] [Related]
4. Severe Anemia from Multiple Gastric Hyperplastic Polyps in a Hemodialysis Patient after Long-term Use of a Proton-pump Inhibitor.
Ikeda S; Takahashi T; Tandoh T; Ushiyama K; Kida Y
Intern Med; 2024; 63(5):649-657. PubMed ID: 38432892
[TBL] [Abstract][Full Text] [Related]
5. Pachydermoperiostosis combined with pyloric gland adenoma with foveolar-type adenoma.
Long B; Jiang C; Zheng Q; Wan P
United European Gastroenterol J; 2024 Feb; 12(1):152-154. PubMed ID: 37991153
[No Abstract] [Full Text] [Related]
6. Long-term follow-up of patients developing gastric mucosal lesions after initiating the potassium-competitive acid blocker vonoprazan.
Kubo K; Kimura N
Clin Endosc; 2024 Apr; ():. PubMed ID: 38632966
[No Abstract] [Full Text] [Related]
7. Vonoprazan-associated long QT syndrome.
Kubo K; Sakakibara T; Yonezawa K; Kato M
J Gen Fam Med; 2022 Jan; 23(1):54-55. PubMed ID: 35004113
[TBL] [Abstract][Full Text] [Related]
8. Bleeding Gastric Polyps: A Rare Presentation of Renal Cell Carcinoma Metastasis.
Schalet R; Jacob AM; El Khoury A; Borum ML; Younes M; Bhattacharya S
Am J Gastroenterol; 2024 Mar; ():. PubMed ID: 38546124
[No Abstract] [Full Text] [Related]
9. Folate and cardiovascular disease.
Otsu Y; Ae R; Kuwabara M
Hypertens Res; 2023 Jul; 46(7):1816-1818. PubMed ID: 37173431
[No Abstract] [Full Text] [Related]
10. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia.
Hashimoto H; Takeuchi M; Kawakami K
Clin Rheumatol; 2023 Nov; 42(11):3075-3082. PubMed ID: 37486577
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of Chinese psoriatic patients for early referral of arthritis using psoriasis epidemiology screening tool: A cross-sectional analysis from the registry database of Chinese Psoriasis Standardized Diagnosis and Treatment Center.
Xia P; Chen J; Yang M; Dong J; Zhou X; Hu F; Chen L
Chin Med J (Engl); 2023 Aug; 136(16):1999-2001. PubMed ID: 37468997
[No Abstract] [Full Text] [Related]
12. Mirikizumab for the treatment of moderate to severe ulcerative colitis.
Hanzel J; Ma C; Jairath V
Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925
[TBL] [Abstract][Full Text] [Related]
13. Ischemic cerebral stroke risk under psoriasis and psoriatic arthritis treatment: A real-world observational study from the French national healthcare system database.
Bulsei J; Fontas E; Hubiche T; Passeron T
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):e1447-e1448. PubMed ID: 37458687
[No Abstract] [Full Text] [Related]
14. Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
Kondo T
Int J Urol; 2023 Sep; 30(9):777-778. PubMed ID: 37452557
[No Abstract] [Full Text] [Related]
15. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
Yoshida T; Kumagai T; Toyozawa R; Katayama R; Nishio M; Seto T; Goto K; Yamamoto N; Ohe Y; Kudou K; Asato T; Zhang P; Nakagawa K
Cancer Sci; 2023 Sep; 114(9):3698-3707. PubMed ID: 37434391
[TBL] [Abstract][Full Text] [Related]
16. Association Between the COVID-19 Pandemic and Early Childhood Development.
Sato K; Fukai T; Fujisawa KK; Nakamuro M
JAMA Pediatr; 2023 Sep; 177(9):930-938. PubMed ID: 37428500
[TBL] [Abstract][Full Text] [Related]
17. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D; De Cillis S; Schulman C; Kadner G; Fiori C; Porpiglia F
Minerva Urol Nephrol; 2023 Dec; 75(6):743-751. PubMed ID: 37350585
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma.
Abe Y; Sasaki M; Takezako N; Ito S; Suzuki K; Handa H; Chou T; Yoshida T; Mori I; Shinozaki T; Suzuki K
Ann Hematol; 2023 Sep; 102(9):2493-2504. PubMed ID: 37341778
[TBL] [Abstract][Full Text] [Related]
19. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics.
Mitsuboshi S; Hamano H; Niimura T; Ozaki AF; Patel PM; Lin TJ; Tanaka Y; Kimura I; Iwata N; Shiromizu S; Chuma M; Koyama T; Yamanishi Y; Kanda Y; Ishizawa K; Zamami Y
Int J Cancer; 2023 Oct; 153(8):1472-1476. PubMed ID: 37306521
[TBL] [Abstract][Full Text] [Related]
20. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Casca F; Macé S; Risse ML; Moreau P
Blood Cancer J; 2023 May; 13(1):72. PubMed ID: 37156782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
